Randomized phase II study of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabine
Not Applicable
Recruiting
- Conditions
- patients with unresectable advanced or recurrent pancreatic cancer
- Registration Number
- JPRN-UMIN000027631
- Lead Sponsor
- agoya University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have allergies to traditional Chinese medicine 2) Patients with mental disorder or severe co-morbidity such as heart failure, renal failure, or bowel obstruction 3) Patients with pregnancy 4) Patients with intorerable of oral medications 5) Patients with active cancer of other organs 6) Patients who are judged inappropriate for the study responsible doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of fatigue and malaise by Cancer Fatigue Scale (CFS)
- Secondary Outcome Measures
Name Time Method